Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $10.00 Average Price Target from Analysts

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have earned a consensus rating of "Buy" from the eight brokerages that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $10.00.

Several equities research analysts have recently issued reports on ACRS shares. Wall Street Zen lowered shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 8th. Scotiabank lowered their target price on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating on the stock in a research note on Friday, May 9th. Cantor Fitzgerald started coverage on shares of Aclaris Therapeutics in a research note on Tuesday, March 18th. They set an "overweight" rating on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $16.00 target price (down from $20.00) on shares of Aclaris Therapeutics in a research note on Wednesday, May 14th.

Institutional Trading of Aclaris Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. acquired a new stake in Aclaris Therapeutics in the 4th quarter valued at approximately $23,876,000. Vivo Capital LLC acquired a new stake in Aclaris Therapeutics in the 4th quarter valued at approximately $22,044,000. Rock Springs Capital Management LP increased its holdings in Aclaris Therapeutics by 125.3% in the 4th quarter. Rock Springs Capital Management LP now owns 6,204,309 shares of the biotechnology company's stock valued at $15,387,000 after purchasing an additional 3,450,814 shares during the last quarter. RA Capital Management L.P. acquired a new stake in Aclaris Therapeutics in the 4th quarter valued at approximately $11,573,000. Finally, Millennium Management LLC increased its holdings in Aclaris Therapeutics by 111.0% in the 1st quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company's stock valued at $6,325,000 after purchasing an additional 2,175,101 shares during the last quarter. Institutional investors and hedge funds own 98.34% of the company's stock.

Aclaris Therapeutics Price Performance

ACRS remained flat at $1.26 during midday trading on Friday. The company's stock had a trading volume of 404,328 shares, compared to its average volume of 1,182,429. The business has a fifty day moving average of $1.33 and a 200 day moving average of $2.20. The stock has a market cap of $136.43 million, a price-to-earnings ratio of -2.42 and a beta of 0.42. Aclaris Therapeutics has a 12 month low of $0.95 and a 12 month high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.07. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. On average, research analysts anticipate that Aclaris Therapeutics will post -0.82 EPS for the current fiscal year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.